Anupam Rasayan Q4 FY26 sales rise 27%, PAT slips

Key takeaway from the March 2026 quarter

Anupam Rasayan India reported its consolidated quarterly results for the quarter ended March 2026 (Q4 FY26), showing strong year-on-year growth in revenue but a decline in net profit. Consolidated net sales for the quarter came in at Rs 635.78 crore, up 27.12% from Rs 500.16 crore in the March 2025 quarter. However, quarterly net profit fell to Rs 42.65 crore in March 2026 from Rs 44.57 crore in March 2025, a decline of 4.31%. The numbers highlight a quarter where topline momentum did not translate into higher bottomline performance.

Consolidated Q4 FY26: Sales up, profit down

For Q4 FY26, the company’s consolidated sales growth was visible in the headline net sales figure of Rs 635.78 crore. The comparative base for March 2025 was Rs 500.16 crore. Profit after tax (PAT) was Rs 42.65 crore for March 2026, compared with Rs 44.57 crore a year earlier. Operating profitability indicators in the provided results table showed OPM at 21.59% for the March 2026 quarter versus 28.88% in March 2025. PBDT for the quarter stood at Rs 98.75 crore versus Rs 118.77 crore, while PBT was Rs 56.07 crore versus Rs 88.12 crore.

Full-year FY26: sharp growth in both revenue and profit

For the full year ended March 2026, Anupam Rasayan India reported consolidated net profit of Rs 170.12 crore, up 82.24% from Rs 93.35 crore in FY25. Full-year consolidated sales rose 64.61% to Rs 2,365.46 crore from Rs 1,436.97 crore in FY25. The results table also listed FY26 OPM at 22.19% compared with 27.90% in FY25. PBDT for FY26 was Rs 394.30 crore versus Rs 300.13 crore in FY25, while PBT was Rs 254.40 crore versus Rs 197.85 crore.

Where the March 2026 quarter sits versus recent quarters

The data shared also included a consolidated quarterly sales series that shows how revenue moved across the last several quarters. Net sales were Rs 731.40 crore in September 2025, followed by Rs 512.45 crore in December 2025 and Rs 635.78 crore in March 2026. The March 2025 quarter sales were Rs 500.16 crore, which serves as the year-ago base for Q4 FY26. This sequence underlines volatility across quarters even as the year-on-year comparison for March 2026 remains positive.

Standalone update: March 2026 net sales

Alongside the consolidated numbers, the provided text also referenced standalone performance for March 2026. Anupam Rasayan’s standalone March 2026 net sales were reported at Rs 370.58 crore, up 12.07% year-on-year. The standalone figure is separate from the consolidated result, but it adds context to how much of the group’s revenue base is coming from consolidated entities.

Management commentary: operating cash flow in FY26

In the transcript excerpt included in the input, the company said it delivered operating cash flow of Rs 334 crores during FY26. The stated drivers were improved asset utilization, operational efficiency, and better working capital management. While cash flow figures do not directly explain quarterly PAT movement, the FY26 operating cash flow number provides additional colour on the company’s internal performance levers during the year.

Business mix reference from the FY26 commentary

The same transcript excerpt described the company’s standalone vertical-wise revenue mix for FY26. It stated that the agrochemical segment contributed 55% of revenue, pharma contributed 20%, performance material contributed 18%, and the balance 7% came from personal care. This mix indicates that agrochemicals remained the largest contributor in the standalone business, with pharma and performance material together forming a meaningful share.

Strategic developments referenced: Jayhawk Fine Chemicals acquisition

The input also referenced a strategic development that the company announced earlier in FY26, relating to an agreement to acquire US-based Jayhawk Fine Chemicals Corporation. The text also stated that Anupam Rasayan’s stock surged following its $150 million acquisition of US-based Jayhawk Fine Chemicals. The excerpted management commentary additionally mentioned that consolidated highlights include Tanfac and one month and two days of Jay-Hawks for Q4 FY26.

Snapshot table: Q4 and FY results in one view

Market impact: what the numbers signal

The reported results show a clear divergence between revenue growth and profitability in the March 2026 quarter. Despite a 27.12% rise in quarterly sales, PAT declined by 4.31% year-on-year, alongside lower OPM, PBDT and PBT versus the year-ago quarter. For the full year, the company delivered strong expansion in both revenue and net profit, with FY26 sales up 64.61% and PAT up 82.24% over FY25. Investors tracking the company’s performance typically focus on whether the Q4 margin profile normalises in later quarters and how consolidation effects, including Tanfac and Jayhawk, reflect in financial metrics.

Conclusion

Anupam Rasayan India ended FY26 with a sharp rise in consolidated sales to Rs 2,365.46 crore and higher net profit of Rs 170.12 crore, even as Q4 FY26 profitability dipped year-on-year. The next updates to watch are subsequent quarterly disclosures that clarify the sustainability of topline growth and the consolidated contribution of acquired or consolidated entities mentioned in the FY26 commentary.